Cipralex significantly reduces the risk of relapse in patients with OCD
Kaplan-Meier survival analysis of relapse(ref 1.)
Cipralex has a statistically significantly superior effect relative to placebo on the time to relapse of OCD
Patients in remission (ref 1)
During Weeks 20 to 40, a significantly higher percentage of Cipralex(escitalopram)-treated patients responded to treatment compared with placebo-treated patients:
Week 20, p<0.01
Weeks 22–40, p<0.001
References
1. N. Fineberg et al. European Neuropsychopharmacology 2007, in press